Executive Summary

Technology assessment on negative pressure wound therapy devices.

Executive Summary

The Center for Medicare Management at the Centers for Medicare and Medicaid Services (CMS) requested this report from The Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ). AHRQ assigned this report to the following Evidence-based Practice Center: ECRI Institute EPC (Contract Number: 290-2007-10063).

Section 154 (c) (3) of the Medicare Improvements for Patient and Providers Act (MIPPA) of 2008 calls for the Secretary of Health and Human Services to perform an evaluation of the Healthcare Common Procedure Coding System (HCPCS) coding decisions for Negative Pressure Wound Therapy (NPWT) devices. Specifically, the evaluation of existing HCPCS codes for NPWT should:

  • ensure accurate reporting and billing for items and services under such codes; and
  • use an existing process for the consideration of coding changes and consider all relevant studies and information furnished pursuant to such processes.

The HCPCS Level II coding system is a comprehensive, standardized system that classifies similar products that are medical in nature into categories for the purpose of efficient claims processing. Products are classified based on similarities in function and whether the products exhibit significant therapeutic distinctions from other products. Currently, all NPWT devices are classified into the same HCPCS codes. The Healthcare Common Procedures Coding System (HCPCS) code E2402 applies to the pump (NEGATIVE PRESSURE WOUND THERAPY ELECTRICAL PUMP, STATIONARY OR PORTABLE) and HCPCS code A6550 applies to the dressing sets (WOUND CARE SET, FOR NEGATIVE PRESSURE WOUND THERAPY ELECTRICAL PUMP, INCLUDES ALL SUPPLIES AND ACCESSORIES). HCPCS code A7000 applies to the canister that goes with the pump.

Negative pressure wound therapy (NPWT) applies a localized vacuum to draw the edges of the wound together while providing a moist environment conducive to rapid wound healing. The development of negative pressure techniques for wound healing is based on two theories: (1) the removal of excess interstitial fluid decreases edema and concentrations of inhibitory factors, and increases local blood flow; and (2) stretching and deformation of the tissue by the negative pressure is believed to disturb the extracellular matrix and introduce biochemical responses that promote wound healing.

NPWT systems include a vacuum pump, drainage tubing, and a dressing set. The pump may be stationary or portable, may rely on AC or battery power, allows for regulation of the suction strength, has alarms to indicate loss of suction, and has a replaceable collection canister. The dressing sets may contain either foam or gauze dressing to be placed in the wound and an adhesive film drape for sealing the wound. The drainage tubes come in a variety of configurations depending on the dressings used or wound being treated. NPWT Systems currently available in the U.S. are listed in Table 1.

Table 1. Negative Pressure Wound Therapy Devices Marketed in the U.S.

Manufacturer

Trade or Brand Names of
Negative Pressure Wound Therapy Devices

Blue Sky Medical Group
6965 El Camino Real, Suite 105-602
La Costa, CA 92009

(Blue Sky Medical Group is now owned by Smith & Nephew, Inc.)

V1STA Negative Wound Therapy (portable unit)
EZCARE Negative Wound Therapy (stationary unit)
Boehringer Wound Systems, LLC
P.O. Box 910
Norristown, PA 19404
Engenex® Advanced NPWT System
(Boehringer Laboratory Suction Pump System)

ConvaTec (Skillman, NJ) markets and distributes the Engenex® NPWT system

Innovative Therapies Inc.
10948 Beaver Dam Rd, Suite C
Hunt Valley, MD 21030
SVEDMAN™ and SVED™ Wound Treatment Systems
Kalypto Medical
6393 Oakgreen Ave.
Hastings, MN 55033

(Iasis Medical, Inc.)

NPD 1000 Negative Pressure Wound Therapy System
(no manufacturer information currently available from a Web site)
KCI, USA Inc. (Kinetic Concepts, Inc.)
8023 Vantage Dr.
San Antonio, TX 78230
InfoV.A.C.® Therapy Unit (stationary unit)
ActiV.A.C.® Therapy Unit (portable unit)
V.A.C.® Freedom™
V.A.C.® ATS™
V.A.C.® Instill System (delivery of topical solutions)
Medela AG Medical Equipment
Laettichstrasse 4b
6341 Baar
Switzerland;

Medela Healthcare
Medela Inc.
1101 Corporate Drive
McHenry, IL 60050

Invia Liberty Wound Therapy (portable)
Invia Vario 18 c/i Wound Therapy (stationary, mobile with battery)
MediTop BV
Vlasakker 22
3417 XT Montfoort
The Netherlands;

The Medical Company
P.O. Box 2116
3800 CC Amersfoort
The Netherlands

Exusdex® wound drainage pump
Premco Medical Systems, Inc.
699 Main Street
New Rochelle, NY 10801 USA
Prodigy™ NPWT System (PMS-800 and PMS-800V)
Prospera
2831 Bledsoe Street
Fort Worth, TX 76107
(Prospera Technologies LLC owns the
Prospera NPWT systems and brand)

PRO-I™ (stationary and portable)
PRO-II™ (portable)
PRO-III™(stationary and portable)

Smith & Nephew, Inc.
970 Lake Carillon Drive, Suite 110
St. Petersburg, FL 33716
V1STA Negative Pressure Wound Therapy (portable unit)
EZCARE Negative Pressure Wound Therapy (stationary unit)
RENASYS™ EZ Negative Pressure Wound Therapy
Talley Group, Ltd.
Premier Way
Abbey Park
Romsey, Hants SO 51 9 DQ England;

U.S. Talley Medical
4740 Ladestone Dr.
Williamston, MI 48895

Venturi™ Negative Pressure Wound Therapy (portable or stationary)

Return to Contents

Methods of the Review

The Centers for Medicare and Medicaid Services (CMS) have partnered with the Agency for Healthcare Research and Quality (AHRQ) to commission a review of NPWT devices as required by the MIPPA legislation. AHRQ contracted with one of its Evidence-based Practice Centers (EPCs), the ECRI Institute EPC, to perform the review. The purpose of this review is to provide information to CMS to consider along with other inputs in evaluating HCPCS coding for NPWT devices. CMS will use this review in its assessment of whether existing HCPCS codes adequately reflect the range of NPWT devices on the market today.

The process of systematic review as practiced by the EPC Program follows specific prescribed steps:

  1. The investigators start with formulated "key" questions. These questions test hypotheses and are structured using the "PICO" framework: patients, intervention of interest, comparator, and outcomes. EPC are encouraged to focus on outcomes that are relevant and important to patients (patient-oriented outcomes). The framework is depicted visually in the "analytic framework" that the EPC program uses to show the relationship between the key questions and the outcomes used to address these questions. (See, for example, Figure 1.)
  2. Inclusion and exclusion criteria for studies to be used in the review are determined based on the specific questions to be addressed. Criteria may vary for each question in the review.
  3. Next, an objective and comprehensive search of the medical literature and "gray literature," (i.e., reports, monographs and studies produced by government agencies, educational facilities and corporations that do not appear in the peer-reviewed literature) is conducted. The reference lists of included studies are examined for any studies not identified by electronic searches.
  4. Studies are compared to the inclusion criteria developed prior to examining the evidence, and those included in the review are then critically appraised, noting features of the design and conduct of the studies that create potential for bias. Bias, in this context, is a study feature that could impact whether the treatment being studied is responsible for the outcomes observed. Studies with a low potential for bias are typically described as being of "high quality," whereas those with high potential for bias are described as being of "low" or "poor" quality, and those of moderate quality as having intermediate potential for bias. The degree to which a study protects against bias is referred to as "internal validity." Following this appraisal, data are extracted from the included studies and analyzed or summarized as appropriate.

After receiving the work assignment for this review in December, 2008, we developed the following Key Questions:

  1. Does any single NPWT system have a significant therapeutic distinction in terms of wound healing outcomes compared to any other NPWT system for the treatment of acute or chronic wounds?
  2. Does any component of a NPWT system have a significant therapeutic distinction in terms of wound healing outcomes compared to any other similar component of a NPWT system for the treatment of acute or chronic wounds?
  3. What are the reported occurrences of pain, bleeding, infection, other complications, and mortality for NPWT systems?
  4. Do patients being treated with one NPWT system have a significant therapeutic distinction in terms of less pain, bleeding, infection, other complications, or mortality than other NPWT systems?

For the purpose of addressing these Key Questions, we considered any NPWT system or component commercially marketed within the past 20 years. In-house developed, noncommercial devices (what might be considered "home-made" negative pressure devices) were excluded. In addressing the questions, we sought the specific outcomes depicted in the analytic framework in Figure 1. According to guidance provided by the U.S. Food and Drug Administration (FDA), we considered improved wound healing and improved wound care to be the most important clinical outcomes associated with the use of a wound-treatment device. The most important outcomes to consider under the category of improved wound healing are percent of patients with complete wound closure and time to complete healing (partial healing for facilitation of surgical wound closure). Improvements in wound care can potentially reduce the occurrence of conditions such as infection that can interfere with proper wound healing. Thus, measuring the impact of NPWT on the occurrence or healing of infections, as well as its impact on the incidence of sepsis, edema, or amputation is important. In addition to these outcomes, we consider other outcomes important to patients, such as quality of life, satisfaction with treatment, duration of treatment, and survival, in keeping with the methods guidance for the EPC Program.

Figure 1. Analytic Framework

For text description, go to [D] Select for Text Description below.

[D] Select for Text Description

Note:

  • In keeping with guidance provided by the FDA, in this report we considered improved wound healing and improved wound care to be the most important clinical outcomes. The most important outcomes to consider under the category of improved wound healing are percent of patients with complete wound closure and time to complete healing (particularly when NPWT is used to prepare a wound for surgical closure). Please note: process indicators such as improved compliance, convenience and personal preference (and patient oriented outcomes such as quality of life or satisfaction with treatment) are considered by CMS to be significant distinctions only to the extent that they result in demonstrably improved clinical outcomes.
  • Improved wound condition as presented in the Analytic Framework is defined as a reduction in wound exudate and infectious materials; the promotion of granulation tissue formation and perfusion; an improvement in graft appearance; a reduction in odor; and a greater rate of epithelialization.

Inclusion and exclusion criteria were then developed to specify the types of studies appropriate for addressing each of these Key Questions. These criteria are explained in detail in the Methods section of this report, but are briefly described here. To address the key questions that consider whether one NPWT system or its components has a significant therapeutic distinction compared to another NPWT system or its components, we included any controlled study that used a NPWT system for the treatment of chronic or acute wounds. (Components of a NPWT system include the pump, the tubing, the dressing kits, and the services provided as part of the NPWT system.) Questions 1, 2 and 4 require comparative studies of different NPWT systems or components. For Key Question 2, studies were required that compared different dressing sets, tubing, or pumps while maintaining identical components for the other parts of an NPWT system. In other words, both groups in the study would need to be receiving NPWT.

In keeping with the methods of the EPC Program, we planned to perform "adjusted indirect comparisons" if no studies directly comparing NPWT systems or components were available.(1,2) Appropriate indirect comparisons can only be performed when randomized controlled trials (RCTs) have compared the interventions of interest to a third, common comparator. In adjusted indirect comparisons, the comparison of the intervention of interest (i.e., different NPWT systems) is adjusted by the results of their direct comparison with a common control group (e.g., standard wound therapy).(3) The validity of an adjusted indirect comparison depends on the internal validity and similarity of the included trials. Thus, to be considered for inclusion in an indirect comparison, studies would be similar in terms of quality, similar for factors related to applicability (population, interventions, and settings), and similar in measurement of outcomes including the incidence of adverse events.(3-6) The use of nonrandomized studies for indirect comparisons is not considered scientifically valid because of the many confounding variables that cannot be accounted for in such comparisons.(7) Even when RCTs are available for indirect comparisons, the conclusions must be framed cautiously because of the difficulty in assuring that the trial features are truly similar enough.

To address Key Question 3 regarding reported occurrences of adverse events for NPWT, we included case series and uncontrolled trials.

Searches were undertaken of 13 electronic bibliographic databases from 1950 to the present for published primary clinical studies and any secondary publications. To supplement the electronic searches, we manually reviewed the reference lists of studies meeting inclusion criteria. In addition, we searched for ongoing clinical trials using ClinicalTrials.gov and Controlledtrials.com. In the interest of being certain that our searches identified all relevant studies, we invited manufacturers, professional organizations, the FDA and the Centers for Medicare & Medicaid Services (CMS) to submit the following:

  • A current product label (requested of industry stakeholders only)
  • Published randomized controlled trials, observational studies, or other compelling clinical evidence examining the use of NPWT devices to impact relevant clinical outcomes
  • Unpublished randomized controlled trials, observational studies, or other compelling clinical evidence examining the use of NPWT devices to impact relevant clinical outcomes.

The materials received were then assessed against the a priori inclusion criteria for each Key Question. Over 1,400 individual items were submitted by interested stakeholders for possible inclusion in the report. All items were reviewed for their relevance to the key questions. None of the submissions were studies directly comparing different NPWT devices or systems. We identified one additional systematic review (8), three comparison studies evaluating NPWT vs. a comparator treatment (9-11), and 23 uncontrolled case series (12-34) that met the inclusion criteria for consideration but which had not been identified by our electronic searches. In addition, we included one unpublished case series submitted by Smith and Nephew (35) giving us a total of 24 additional case series included in this report. Figure 2 is an attrition diagram that provides a visualization of the disposition of materials as they were evaluated for possible inclusion in the report.

Figure 2 .  Disposition of Documents Identified by Internal Searches and Outside Submissions

For text description, go to [D] Select for Text Description below.

[D] Select for Text Description

Note: Language has been corrected to reflect screening of meeting abstracts, poster presentations and other documents in addition to abstracts and full articles.

The most common reasons for exclusion of submitted materials were

  • personal statements of support for specific NPWT systems that did not include data relevant to this review
  • animal studies
  • studies not relevant to negative pressure wound therapy
  • narrative reviews
  • poster presentations
  • case studies (fewer than five patients)
  • publications that duplicated an already included study

A listing of individual stakeholders with included and excluded submissions including reasons for exclusion are provided in Appendix D.

Next, an assessment of the potential for bias of the included studies was performed using a quality assessment instrument developed by ECRI Institute for comparative studies and the Assessment of Multiple Systematic Reviews (AMSTAR) measurement tool (36) for systematic reviews of the literature.

Return to Contents

Evidence for Negative Pressure Wound Therapy

Key Question 1: Does any single NPWT system have a significant therapeutic distinction in terms of wound healing outcomes compared to any other NPWT system for the treatment of acute or chronic wounds?

No studies directly comparing one NPWT system to another NPWT system that addressed this Key Question were identified by our searches or in the materials submitted by interested parties. We did identify one recently completed trial listed on ClinicalTrials.gov which appears to compare two different systems, but the investigators did not wish to share any information about the trial prior to publication.

Based on our pre-determined methodology, evidence for indirect comparisons was to be obtained from RCTs of commercially available NPWT systems versus a common comparator. Of 40 studies comparing a NPWT system to another wound care therapy, all were studies of the Kinetics Concepts Inc. (KCI) VAC® system, and only nine were RCTs. Therefore no indirect comparisons with other NPWT systems were possible. Despite the fact that we could not use the studies to answer the Key Question, we assessed the studies for risk of bias and extracted data on treatment procedures, patient characteristics, and study outcomes. We have provided tables with this information in Appendix C for the interested reader, and briefly discuss these studies here.

Our quality assessment of the 40 comparison studies indicated that the majority had significant potential for bias. None of the studies received a high-quality rating; seven (18%) were rated moderate, and 33 (82%) were rated low. Typical study limitations included lack of concealment of treatment allocation, lack of blinding of patients and assessors, failure to report patient characteristics, and small study populations. As explained below, these studies comparing NPWT systems to standard wound care did not meet the study design and conduct requirements needed for use in an indirect comparison analysis.

Blinding patients, treating physicians, and outcome assessors to treatment increases the internal validity of studies. In a situation where patients are being treated by NPWT systems, blinding the patient and the physician providing care is probably not feasible. To prevail over these limitations, van den Boogaard et al.(37) recommend overcoming all other potential shortcomings, i.e., wound assessors should be blinded to treatment, patient groups must be comparable, group allocation should be concealed, and full follow-up of a sufficient proportion of all included patients should be performed.

A majority of the studies did not overcome these deficiencies. None of the studies reported that the physicians were blinded to treatment assignment, and only five (12%) of the studies reported blinding of outcome assessors. In only 7% of studies was there concealment of allocation to treatment, one of the most crucial elements of any RCT, with failure to do so typically resulting in selection bias.(38-39)

Only 14 (35%) studies had similar populations, and 30% of the studies did not have similar follow-up times. Over 75% of the studies either reported a potential conflict of interest in terms of funding (k = 9) or made no report of their funding source (k = 22). Lastly, over 50% of the studies had a study size of fewer than 50 patients; 85% of the studies included fewer than 75 patients.

Key Question 2: Does any component of a NPWT system have a significant therapeutic distinction in terms of wound healing outcomes compared to any other similar component of a NPWT system for the treatment of acute or chronic wounds?

No studies directly comparing one NPWT component to another NPWT component (with both groups receiving negative pressure treatment) that addressed this Key Question were identified by our searches or in the materials submitted by interested parties.

Key Question 3: What are the reported occurrences of pain, bleeding, infection, other complications, and mortality for NPWT systems?

Adverse events were reported in 37 of 40 studies comparing NPWT to other treatments. Of the 37 studies reporting events, seven (19%) studies described NPWT as a safe treatment. Fewer complications were reported in the NPWT-treated patients than in those receiving other wound therapies in 19 (51%) studies (9-11, 40-55)) and similar complications were reported in 8 (22%) studies.(56-63) Adverse events reported in 103 case series included pain (k = 12), bleeding (k = 7), infection/bacterial colonization (k = 15), mortality (k = 4), and other complications (k = 18).

Key Question 4: Do patients being treated with one NPWT system have a significant therapeutic distinction in terms of less pain, bleeding, infection, other complications, or mortality than other NPWT systems?

No studies comparing one NPWT system to another NPWT system were identified by our searches, and none were submitted by interested parties. Consequently, we were not able to answer this Key Question. Adverse events described in the studies comparing NPWT to some other form of wound care and in case series are described under Key Question 3.

Return to Contents

Conclusion

Based on our defined search strategies and submissions from interested parties, no studies directly comparing one NPWT system to another NPWT system were identified that addressed Key Questions 1, 2 or 4. Thus, we were not able to identify a significant therapeutic distinction of one NPWT system or component over another through the use of head-to-head comparisons. A recently completed study listed on ClinicalTrials.gov (NCT00583141; NCT00590369) may address this question, but the investigators did not wish to disclose any details of the study design prior to publication. In the absence of head-to-head comparison studies, we examined comparison studies of NPWT systems or components versus a common comparator in hopes of assessing the relative efficacy and/or safety of different NPWT systems using adjusted indirect comparisons. Our review of 40 comparison studies found that all of the controlled trials involved the evaluation of one NPWT device, the V.A.C.® manufactured by KCI. Furthermore, to be considered for inclusion in an indirect comparison, studies must be RCTs and must provide sufficient information to determine their comparability in terms of patient characteristics, patient exclusion/inclusion criteria, methodology, outcome definitions, outcome measures, and application of the comparison treatment. Only nine of the KCI VAC® comparison studies were RCTs and none of these RCTs met the requirements necessary for the indirect comparison option had there been studies of more than one NPWT system. Consequently, at this time the available evidence cannot be used to determine a significant therapeutic distinction of a NPWT system.

Our searches did not identify any studies comparing one NPWT system component to another NPWT system component that addressed Key Question 2. This question was designed to examine studies that compared different dressing sets, tubing, or pumps while maintaining identical components for the other parts of an NPWT system. In particular, we were looking for studies that evaluated gauze versus foam dressing sets in various wound types.

While we were able to capture the severity of harms reported by case series and comparison studies evaluating NPWT to comparator treatments, due to the lack of studies comparing one NPWT system to another NPWT system, we were unable to determine the severity of adverse events for one NPWT system compared to another.

We identified a total of 22 other systematic reviews, all published between 2000 and 2008, that covered NPWT devices. These reviews included studies reporting data on NPWT for patients with a broad range of wound types and focused on comparison to other wound treatments (gauze, bolster dressings, wound gels, alginates, and other topical therapies). The systematic reviews of NPWT reveal several important points about the current state of the evidence on this technology. First, all of the systematic reviews noted the lack of high-quality clinical evidence supporting the advantages of NPWT compared to other wound treatments. The lack of high-quality NPWT evidence resulted in many systematic reviewers relying on low-quality retrospective studies to judge the efficacy of this technology. Second, no studies directly comparing different NPWT components (such as foam vs. gauze dressings) were identified by any of the reviewers.

In their systematic review of clinical studies of NPWT, Peinemann et al.(64) sought to identify unpublished completed or discontinued RCTs to gain a broader knowledge of the NPWT evidence. The authors were concerned that previous systematic review conclusions on efficacy and safety based on published data alone may no longer hold after consideration of unpublished data. The authors invited two NPWT device manufacturers KCI. (V.A.C.®) and BlueSky Medical Group Inc. (Versatile 1 Wound Vacuum System) and authors of conference abstracts to provide information on study status and publication status of sponsored trials. Responses were received from 10 of 17 (59%) authors and both manufacturers. BlueSky Medical Group Inc., however, had not sponsored relevant RCTs and only provided case reports. The authors determined that of 28 RCTs, 13 had been completed, six had been discontinued, six were ongoing, and the status of three could not be determined. Nine trials were unpublished, and no results were provided by the investigators. Peinemann et al. concluded that the "lack of access to unpublished study results data raises doubts about the completeness of the evidence base on NPWT."(64)

Clinical research on NPWT capable of indicating if any one NPWT system or component provides a significant therapeutic distinction requires study design and conduct that will minimize the possibilities for bias. Important study design features that were not typically reported such as concealment of allocation, reporting of randomization methods, use of power analysis to ensure adequate study size, blinding wound assessors, and reporting of complete wound healing data will improve the internal validity and the informativeness of the studies.

Return to Contents

References

1.  Agency for Healthcare Research and Quality (AHRQ). Methods reference guide for effectiveness and comparative effectiveness reviews, Version 1.0. [Draft posted Oct. 2007]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 128 p. Also available: http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf. [Plugin Software Help]

2.  Fu R, Gartlehner G, Grant M, Shamalyan T, Sedrakyan A, Wilt T, Griffith L, Oremus M, Raina P, Ismaila A, Santaguida L, Lau J, Trikalinos T. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective healthcare program [unpublished]. 55 p.

3.  Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ, International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technol Assess 2005 Jul;9(26):1-134, iii-iv. PMID: MEDLINE - PMID:16014203

4.  Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006 Oct 28;368(9546):1503-15. PMID: MEDLINE - PMID:17071284

5.  Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003 Mar 1;326(7387):472. PMID: MEDLINE - PMID:12609941

6.  Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997 Jun;50(6):683-91.

7.  Wells G, Sultan S, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health (CADTH); 2009 Mar. 205 p. Also available: http://www.cadth.ca/media/pdf/H0462_itc_tr_e.pdf. [Plugin Software Help]

8.  Noble-Bell G, Forbes A. A systematic review of the effectiveness of negative pressure wound therapy in the management of diabetes foot ulcers. Int Wound J 2008 Jun;5(2):233-42. PMID: MEDLINE - PMID:18494629

9.  Labler L, Keel M, Trentz O. Vacuum-assisted closure (VAC) for temporary coverage of soft-tissue injury in type III open fracture of lower extremities. Eur J Trauma 2004;30(5):305-12.

10.  Yang CC, Chang DS, Webb LX. Vacuum-assisted closure for fasciotomy wounds following compartment syndrome of the leg. J Surg Orthop Adv 2006 Spring;15(1):19-23. PMID: MEDLINE - PMID:16603108

11.  Timmers MS, Graafland N, Bernards AT, Nelissen RGHH, Van Dissel JT, Jukema GN. Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis. Wound Repair Regen 2009 Mar-Apr;17(2):278-86. PMID: EMBASE (OVID):2009130572

12.  Kotsis T, Lioupis C. Use of vacuum assisted closure in vascular graft infection confined to the groin. Acta Chir Belg 2007 Jan-Feb;107(1):37-44. PMID: MEDLINE - PMID:17405596

13.  Machen MS. Management of traumatic war wounds using vacuum-assisted closure dressings in an austere environment. Army Med Dept J 2007 Jan-Mar;17-23.

14.  Wongworawat MD, Schnall SB, Holtom PD, Moon C, Schiller F. Negative pressure dressings as an alternative technique for the treatment of infected wounds. Clin Orthop Relat Res 2003 Sep;(414):45-8. PMID: MEDLINE - PMID:12966275

15.  Bendo JA, Quirno M, Pelham F, Barone JA, Awad J. Posterior lumbar wound drainage management with vacuum-assisted closure. World Spine J 2007 Sep;2(4):187-90.

16.  Stonerock CE, Bynoe RP, Yost MJ, Nottingham JM. Use of a vacuum-assisted device to facilitate abdominal closure. Am Surg 2003 Dec;69(12):1030-4; discussion 1034-5. PMID: MEDLINE - PMID:14700286

17.  Horn PL, Ruth B, Kean JR. Use of wound V.A.C. therapy in pediatric patients with infected spinal wounds: a retrospective review. Orthop Nurs 2007 Sep-Oct;26(5):317-22; quiz 323-4. PMID: MEDLINE - PMID:17921893

18.  Mooney JF 3rd, Argenta LC, Marks MW, Morykwas MJ, DeFranzo AJ. Treatment of soft tissue defects in pediatric patients using the V.A.C. system. Clin Orthop Relat Res 2000 Jul;(376):26-31. PMID: MEDLINE - PMID:10906854

19.  Ploumis A, Mehbod AA, Dressel TD, Dykes DC, Transfeldt EE, Lonstein JE. Therapy of spinal wound infections using vacuum-assisted wound closure: risk factors leading to resistance to treatment. J Spinal Disord Tech 2008 Jul;21(5):320-3. PMID: MEDLINE - PMID:18600140

20.  Scholl L, Chang E, Reitz B, Chang J. Sternal osteomyelitis: use of vacuum-assisted closure device as an adjunct to definitive closure with sternectomy and muscle flap reconstruction. J Card Surg 2004 Sep-Oct;19(5):453-61. PMID: MEDLINE - PMID:15383060

21.  Bendewald FP, Cima RR, Metcalf DR, Hassan I. Using negative pressure wound therapy following surgery for complex pilonidal disease: a case series. Ostomy Wound Manage 2007 May;53(5):40-6. PMID: MEDLINE - PMID:17551174

22.  Ferron G, Garrido I, Martel P, Gesson-Paute A, Classe JM, Letourneur B, Querleu D. Combined laparoscopically harvested omental flap with meshed skin grafts and vacuum-assisted closure for reconstruction of complex chest wall defects. Ann Plast Surg 2007 Feb;58(2):150-5. PMID: MEDLINE - PMID:17245140

23.  Campbell PE, Smith GS, Smith JM. Retrospective clinical evaluation of gauze-based negative pressure wound therapy. Int Wound J 2008 Jun;5(2):280-6. PMID: MEDLINE - PMID:18494633

24.  Armstrong DG, Lavery LA, Abu-Rumman P, Espensen EH, Vazquez JR, Nixon BP, Boulton AJ. Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot. Ostomy Wound Manage 2002 Apr;48(4):64-8. PMID: MEDLINE - PMID:11993062

25.  Garner GB, Ware DN, Cocanour CS, Duke JH, McKinley BA, Kozar RA, Moore FA. Vacuum-assisted wound closure provides early fascial reapproximation in trauma patients with open abdomens. Am J Surg 2001 Dec;182(6):630-8. PMID: MEDLINE - PMID:11839329

26.  Heller L, Levin SL, Butler CE. Management of abdominal wound dehiscence using vacuum assisted closure in patients with compromised healing. Am J Surg 2006 Feb;191(2):165-72. PMID: MEDLINE - PMID:16442940

27.  Andrews BT, Smith RB, Goldstein DP, Funk GF. Management of complicated head and neck wounds with vacuum-assisted closure system. Head Neck 2006 Nov;28(11):974-81. PMID: MEDLINE - PMID:16983694

28.  Rosenthal EL, Blackwell KE, McGrew B, Carroll WR, Peters GE. Use of negative pressure dressings in head and neck reconstruction. Head Neck 2005 Nov;27(11):970-5. PMID: MEDLINE - PMID:16127668

29.  Stone PA, Hass SM, Flaherty SK, DeLuca JA, Lucente FC, Kusminsky RE. Vacuum-assisted fascial closure for patients with abdominal trauma. J Trauma 2004 Nov;57(5):1082-6. PMID: MEDLINE - PMID:15580036

30.  Isago T, Nozaki M, Kikuchi Y, Honda T, Nakazawa H. Negative-pressure dressings in the treatment of pressure ulcers. J Dermatol 2003 Apr;30(4):299-305. PMID: MEDLINE - PMID:12707466

31.  Avery C, Pereira J, Moody A, Gargiulo M, Whitworth I. Negative pressure wound dressing of the radial forearm donor site. Int J Oral Maxillofac Surg 2000 Jun;29(3):198-200. PMID: MEDLINE - PMID:10970082

32.  Baharestani MM. Negative pressure wound therapy in the adjunctive management of necrotizing fascitis: examining clinical outcomes. Ostomy Wound Manage 2008 Apr;54(4):44-50. PMID: MEDLINE - PMID:18480505

33.  Hersh RE, Jack JM, Dahman MI, Morgan RF, Drake DB. The vacuum-assisted closure device as a bridge to sternal wound closure. Ann Plast Surg 2001 Mar;46(3):250-4. PMID: MEDLINE - PMID:11293515

34.  Perez D, Wildi S, Demartines N, Bramkamp M, Koehler C, Clavien PA. Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg 2007 Oct;205(4):586-92. PMID: MEDLINE - PMID:17903734, MEDLINE - Ovid:17903734

35.  Clinical in-market evaluation interim report. Hull, United Kingdom: Smith & Nephew Medical, Ltd.; 2009 Feb 2. 30 p.

36.  Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10. PMID: MEDLINE - PMID:17302989

37.  Van Den Boogaard M, De Laat E, Spauwen P, Schoonhoven L. The effectiveness of topical negative pressure in the treatment of pressure ulcers: A literature review. Eur J Plastic Surg 2008 Apr;31(1):1-7. PMID: EMBASE (OVID):2008172557

38.  Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg 2008 Jun;95(6):685-92. PMID: MEDLINE - PMID:18446777, EMBASE (OVID):2008405595

39.  Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 Feb 1;273(5):408-12. PMID: MEDLINE - PMID:7823387

40.  Page JC, Newswander B, Schwenke DC, Hansen M, Ferguson J. Retrospective analysis of negative pressure wound therapy in open foot wounds with significant soft tissue defects. Adv Skin Wound Care 2004 Sep;17(7):354-64. PMID: MEDLINE - PMID:15343085, MEDLINE - Ovid:15343085

41.  Ozturk E, Ozguc H, Yilmazlar T. The use of vacuum assisted closure therapy in the management of Fournier's gangrene. Am J Surg 2008 Sep 11. PMID: MEDLINE - PMID:18789410

42.  Wanner MB, Schwarzl F, Strub B, Zaech GA, Pierer G. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. Scand J Plast Reconstr Surg Hand Surg 2003;37(1):28-33. PMID: MEDLINE - PMID:12625392, MEDLINE - Ovid:12625392

43.  Siegel HJ, Long JL, Watson KM, Fiveash JB. Vacuum-assisted closure for radiation-associated wound complications. J Surg Oncol 2007 Dec 1;96(7):575-82. PMID: MEDLINE - PMID:17999398, EMBASE (OVID):2007583978

44.  Fuchs U, Zittermann A, Stuettgen B, Groening A, Minami K, Koerfer R. Clinical outcome of patients with deep sternal wound infection managed by vacuum-assisted closure compared to conventional therapy with open packing: a retrospective analysis. Ann Thorac Surg 2005 Feb;79(2):526-31. PMID: MEDLINE - PMID:15680828, MEDLINE - Ovid:15680828

45.  McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 2000 Aug;46(8):28-32, 34. PMID: MEDLINE - PMID:11189545, MEDLINE - Ovid:11189545

46.  Rinker B, Amspacher JC, Wilson PC, Vasconez HC. Subatmospheric pressure dressing as a bridge to free tissue transfer in the treatment of open tibia fractures. Plast Reconstr Surg 2008 May;121(5):1664-73. PMID: MEDLINE - PMID:18453991, EMBASE (OVID):2008222950

47.  Joseph E, Hamori CA, Bergman S, Roaf E, Swann NF, Anastasi GW. A prospective, randomized trial of vacuum-assisted closure versus standard therapy of chronic non-healing wounds. Wounds 2000;12(3):60-7. Also available: http://www.medscape.com/viewarticle/407550_print.

48.  Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008 Apr;31(4):631-6. PMID: MEDLINE - PMID:18162494, MEDLINE - Ovid:18162494

49.  Ford CN, Reinhard ER, Yeh D, Syrek D, De Las Morenas A, Bergman SB, Williams S, Hamori CA. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the Healthpoint system in the management of pressure ulcers. Ann Plast Surg 2002 Jul;49(1):55-61; discussion 61. PMID: MEDLINE - PMID:12142596, EMBASE (OVID):2002250392

50.  Braakenburg A, Obdeijn MC, Feitz R, van Rooij IA, van Griethuysen AJ, Klinkenbijl JH. The clinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the management of acute and chronic wounds: a randomized controlled trial. Plast Reconstr Surg 2006 Aug;118(2):390-7; discussion 398-400. PMID: MEDLINE - PMID:16874208, MEDLINE - Ovid:16874208

51.  Segers P, De Jong AP, Kloek JJ, De Mol BAJM. Poststernotomy mediastinitis: Comparison of two treatment modalities. Interact Cardiovasc Thorac Surg 2005 Dec 1;4(6):555-60. PMID: EMBASE (OVID):2005556234

52.  Simek M, Hajek R, Fluger I, Zalesak b, Molitor M, Lonsky V, Grulichova J, Langova k. Topical negative pressure versus conventional treatment of deep sternal wound infection in cardiac surgery. EWMA J 2008 Oct;8(3):17-20.

53.  Song DH, Wu LC, Lohman RF, Gottlieb LJ, Franczyk M. Vacuum assisted closure for the treatment of sternal wounds: the bridge between debridement and definitive closure. Plast Reconstr Surg 2003 Jan;111(1):92-7. PMID: MEDLINE - PMID:12496568, MEDLINE - Ovid:12496568

54.  Stannard JP, Robinson JT, Anderson ER, McGwin G Jr, Volgas DA, Alonso JE. Negative pressure wound therapy to treat hematomas and surgical incisions following high-energy trauma. J Trauma 2006 Jun;60(6):1301-6. PMID: MEDLINE - PMID:16766975, MEDLINE - Ovid:16766975

55.  Schwien T, Gilbert J, Lang C. Pressure ulcer prevalence and the role of negative pressure wound therapy in home health quality outcomes. Ostomy Wound Manag 2005;51:47-60. PMID: MEDLINE - PMID:16230764

56.  Armstrong DG, Lavery LA, Boulton AJ. Negative pressure wound therapy via vacuum-assisted closure following partial foot amputation: what is the role of wound chronicity? Int Wound J 2007 Mar;4(1):79-86. PMID: MEDLINE - PMID:17425550, MEDLINE - Ovid:17425550

57.  Huang WS, Hsieh SC, Hsieh CS, Schoung JY, Huang T. Use of vacuum-assisted wound closure to manage limb wounds in patients suffering from acute necrotizing fasciitis. Asian J Surg 2006 Jul;29(3):135-9. PMID: MEDLINE - PMID:16877210, MEDLINE - Ovid:16877210

58.  Doss M, Martens S, Wood JP, Wolff JD, Baier C, Moritz A. Vacuum-assisted suction drainage versus conventional treatment in the management of poststernotomy osteomyelitis. Eur J Cardiothorac Surg 2002 Dec 1;22(6):934-8. PMID: MEDLINE - PMID:12467816, EMBASE (OVID):2002445084

59.  Domkowski PW, Smith ML, Gonyon Jr DL, Drye C, Wooten MK, Levin LS, Wolfe WG. Evaluation of vacuum-assisted closure in the treatment of poststernotomy mediastinitis. J Thorac Cardiovasc Surg 2003 Aug 1;126(2):386-90. PMID: MEDLINE - PMID:12928634, EMBASE (OVID):2003351541

60.  Immer FF, Durrer M, Muhlemann KS, Erni D, Gahl B, Carrel TP. Deep sternal wound infection after cardiac surgery: modality of treatment and outcome. Ann Thorac Surg 2005 Sep;80(3):957-61. PMID: MEDLINE - PMID:16122463, MEDLINE - Ovid:16122463

61.  Genecov DG, Schneider AM, Morykwas MJ, Parker D, White WL, Argenta LC. A controlled subatmospheric pressure dressing increases the rate of skin graft donor site reepithelialization. Ann Plast Surg 1998 Mar;40(3):219-25. PMID: MEDLINE - PMID:9523602, EMBASE (OVID):1998076092

62.  Scherer LA, Shiver S, Chang M, Meredith JW, Owings JT, Tominaga GT, Schecter WP, Parks SN, Peck J, Mayberry J. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg 2002;137(8):930-4. PMID: MEDLINE - PMID:12146992, EMBASE (OVID):2002281916

63.  Stone P, Prigozen J, Hofeldt M, Hass S, DeLuca J, Flaherty S. Bolster versus negative pressure wound therapy for securing split-thickness skin grafts in trauma patients. Wounds 2004;16(7):219-23.

64.  Peinemann F, McGauran N, Sauerland S, Lange S. Negative pressure wound therapy: Potential publication bias caused by lack of access to unpublished study results data. BMC Med Res Methodol 2008;8:4. PMID: MEDLINE - PMID:18267008, EMBASE (OVID):2008179754

Return to Table of Contents

Abbreviations and Acronyms

Abbreviation / AcronymsFull Term
ABIAnkle brachial index
AFAtrial fibrillation
AMWTAdvanced moist wound therapy
ASAortic stenosis
BMIBody mass index
CACan’t answer
CABGCoronary artery bypass surgery
CADCoronary artery disease
CASCarotid artery stenosis
CCCubic centimeter
CHFCongestive heart failure
CDCoronary disease
CDIClosed drainage and irrigation
CDTClosed drainage technique
CHDCoronary heart disease
CHFCongestive heart failure
CIConfidence interval
CKDChronic kidney disease
CLDChronic lung disease
CMCentimeter
CNPContinuous negative pressure
COPDChronic obstructive pulmonary disorder
CRFChronic renal failure
DDay(s)
DEDDe-epidermalized dermis
DFUDiabetic foot ulcer
DMDiabetes mellitus
DSWIDeep sternal wound infection
EQ-5DEuroQol 5 Dimensions Index
ESRDEnd stage renal disease
ESRFEnd stage renal failure
FFemale
F/UFollow-up
gm/dlGrams per deciliter
HFHeart failure
HPHealthpoint System
ICGIndocyanine Green
IDDMInsulin dependent diabetes mellitus
IHDIschaemic heart disease
IQRInterquartile range
ISSInjury Severity Score
LLength
LOSLength of hospital stay
LVEFLeft ventricular ejection fraction
MMale
mg/lMilligram per liter
MIMyocardial infarction
mlMilliliter
mmHgMillimeters of mercury
MRIMagnetic resonance imaging
MWMoist to wet
NANot applicable
NIDDMNon insulin dependent diabetes mellitus
NPITNegative pressure instillation therapy
NPWTNegative pressure wound therapy
NRNot reported
NSNot significant
OROperating room
PAPeripheral arteriopathy
PADPeripheral arterial disease
PAODPeripheral artery occlusive disease
PMPost-sternotomy mediastinitis
PPIPresent pain intensity
PUPolyurethane
PVAPolyvinyl alcohol
PVDPeripheral vascular disease
QOLQuality of life
RCTRandomized controlled trial
RDRenal disease
RFRenal failure
ROCFReticulated open cell foam
RRRisk ratio
SF-36Short Form 36
SF-MPQShort Form-McGill Pain Questionnaire
SIGNScottish Intercollegiate Guideline Network
SOCStandard of care
SOMPost-sternotomy osteomyelitis
SRSystematic review
SSDSilver sulphadiazine crème
SSISurgical site infection
STSGSplit thickness skin graft
SWTStandard wound therapy
TNPTopical negative pressure
TPNTotal parenteral nutrition
umMicrometer
VACVacuum-assisted closure
VASVisual analogue scale
WWidth
WDSWounds
WMWet to moist
WMDWeighted mean differences
Current as of November 2009
Internet Citation: Executive Summary. November 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/research/findings/ta/negative-pressure-wound-therapy/executive-summary.html